{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:27:43Z","timestamp":1790767663999,"version":"4.1.0"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["UG1CA189867"],"award-info":[{"award-number":["UG1CA189867"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Female cancer survivors often experience estrogen-deprivation symptoms, which may lead to decreases in sexual desire, vulvovaginal health (lubrication, dryness, discomfort), and sexual satisfaction. Interventions are needed to address these concerns.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>The objective of this secondary analysis was to determine if women with higher (better) scores on the Female Sexual Function Index (FSFI) lubrication and pain subscales reported higher desire scores based on treatment with bupropion vs placebo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Participants were part of NRG Oncology\u2019s NRG-CC004 (NCT03180294), a randomized placebo-controlled clinical trial evaluating bupropion (150 vs 300\u00a0mg) to improve sexual desire in survivors of breast or gynecologic cancer. All participants with baseline data from the FSFI lubrication, pain, and desire subscales with 5- and\/or 9-week data were analyzed. The FSFI subscale scores were correlated using Spearman correlation coefficients. Logistic regression was used to determine associations between FSFI desire and other FSFI subscales while accounting for treatment arm and other covariates.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcomes<\/jats:title>\n                  <jats:p>The primary outcome of NRG Oncology\u2019s NRG-CC004 (NCT03180294) randomized phase II dose-finding trial was change from baseline to 9\u00a0weeks on the FSFI desire subscale score. Similar to the parent study, the primary outcome for this ancillary data study was the FSFI desire subscale score at 5 and 9\u00a0weeks.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 230 participants completed the FSFI at baseline and 189 at 9\u00a0weeks. The strongest correlations were between lubrication and pain at baseline (all participants, rho\u00a0=\u20090.77; bupropion arms, rho\u2009=\u20090.82), week 5 (all participants, rho\u2009=\u20090.71; bupropion arms, rho\u2009=\u20090.68), and week 9 (all participants, rho\u2009=\u20090.75; bupropion arms, rho\u2009=\u20090.78), and the weakest correlations were between desire and pain. In patients in the treatment arms there were no interactions between lubrication or pain.<\/jats:p>\n                  <jats:p>The impact of various covariates on the FSFI score for desire at 9\u00a0weeks demonstrated that participants of non-White race (odds ratio [OR],\u00a00.42; 95% CI, 0.21-0.81; P\u00a0=\u2009.010), with a high lubrication score (OR,\u00a00.36; 95% CI, 0.21-0.61; P\u00a0=\u2009.0002), with a high pain score (less pain) (OR,\u00a00.50; 95% CI, 0.29-0.87; P\u00a0=\u2009.014), or with prior pelvic surgery (OR,\u00a00.38; 95% CI, 0.23-0.63; P\u00a0=\u2009.0002) had lower odds of having low desire.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Implications<\/jats:title>\n                  <jats:p>Acute estrogen-deprivation symptoms should be addressed prior to sexual desire intervention.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Strengths and Limitations<\/jats:title>\n                  <jats:p>This secondary analysis was not powered to examine all variables.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Lubrication and pain were predictors of low desire. Therefore, vulvovaginal atrophy and associated genitourinary symptoms of menopause such as vaginal dryness and dyspareunia should be addressed prior to or in parallel with interventions for sexual desire.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jsxmed\/qdae061","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T11:38:52Z","timestamp":1718019532000},"page":"709-715","source":"Crossref","is-referenced-by-count":2,"title":["NRG-CC004 ancillary data study\u2014exploring the effect of bupropion on sexual desire in female cancer survivors with and without vulvovaginal symptoms"],"prefix":"10.1093","volume":"21","author":[{"given":"Jeanne","family":"Carter","sequence":"first","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center , New York, NY 10065 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie L","family":"Pugh","sequence":"additional","affiliation":[{"name":"NRG Oncology Statistics and Data Management Center , Philadelphia, PA 19103 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Arring","sequence":"additional","affiliation":[{"name":"University of Tennessee , Knoxville, TN 37966 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramey D","family":"Littell","sequence":"additional","affiliation":[{"name":"Kaiser Permanente , San Francisco, CA 94115 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth J","family":"Page","sequence":"additional","affiliation":[{"name":"Cancer Center of Kansas , Wichita, KS 67460 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendrith M","family":"Rowland Jr.","sequence":"additional","affiliation":[{"name":"Carle Cancer Institute , Urbana, IL 61801 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judie R","family":"Goodman","sequence":"additional","affiliation":[{"name":"Trinity Health St. Joseph Mercy Oakland , Pontiac, MI 48341 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wajeeha","family":"Razaq","sequence":"additional","affiliation":[{"name":"University of Oklahoma Health Sciences Center , Oklahoma City, OK 73104 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahzad","family":"Siddique","sequence":"additional","affiliation":[{"name":"Mercy Cancer Center , Sacramento, CA 95816 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Borges","sequence":"additional","affiliation":[{"name":"NRG Oncology Statistics and Data Management Center , Philadelphia, PA 19103 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A","family":"Kachnic","sequence":"additional","affiliation":[{"name":"Columbia University Medical Center , New York, NY 10032 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra L","family":"Barton","sequence":"additional","affiliation":[{"name":"University of Tennessee College of Nursing , Knoxville, TN 37996 , United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,10]]},"reference":[{"key":"2024080207042719000_ref1","volume-title":"Cancer Treatment & Survivorship Facts & Figures 2019-2021","author":"American Cancer Society","year":"2019"},{"issue":"5","key":"2024080207042719000_ref2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1200\/JCO.2017.75.8995","article-title":"Interventions to address sexual problems in people with cancer: American Society of Clinical Oncology clinical practice guideline adaptation of Cancer Care Ontario guideline","volume":"36","author":"Carter","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"2024080207042719000_ref3","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/009262300278597","article-title":"The female sexual function index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function","volume":"26","author":"Rosen","year":"2000","journal-title":"J Sex Marital Therapy"},{"issue":"18","key":"2024080207042719000_ref4","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1002\/cncr.26739","article-title":"Psychometric validation of the female sexual function index (FSFI) in cancer survivors","volume":"118","author":"Baser","year":"2012","journal-title":"Cancer"},{"issue":"4","key":"2024080207042719000_ref5","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1200\/JCO.21.01473","article-title":"Randomized controlled phase II evaluation of two dose levels of bupropion versus placebo for sexual desire in female cancer survivors: NRG-CC004","volume":"40","author":"Barton","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"2024080207042719000_ref6","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jsxm.2017.03.258","article-title":"Flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the PLUMERIA study","volume":"14","author":"Portman","year":"2017","journal-title":"J Sex Med"},{"issue":"12","key":"2024080207042719000_ref7","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/annonc\/mdl304","article-title":"An open-label, fixed-dose study of bupropion effect on sexual function scores in women treated for breast cancer","volume":"17","author":"Mathias","year":"2006","journal-title":"Ann Oncol"},{"issue":"1","key":"2024080207042719000_ref8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00926230590475206","article-title":"The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores","volume":"31","author":"Wiegel","year":"2005","journal-title":"J Sex Marital Ther Jan-Feb"},{"issue":"2","key":"2024080207042719000_ref9","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00520-017-3878-2","article-title":"Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (alliance)","volume":"26","author":"Barton","year":"2018","journal-title":"Support Care Cancer"},{"issue":"2","key":"2024080207042719000_ref10","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s11764-016-0585-9","article-title":"Vaginal and sexual health treatment strategies within a female sexual medicine program for cancer patients and survivors","volume":"11","author":"Carter","year":"2017","journal-title":"J Cancer Surviv"},{"issue":"1","key":"2024080207042719000_ref11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00520-020-05472-3","article-title":"A single-arm, prospective trial investigating the effectiveness of a non-hormonal vaginal moisturizer containing hyaluronic acid in postmenopausal cancer survivors","volume":"29","author":"Carter","year":"2021","journal-title":"Support Care Cancer"},{"key":"2024080207042719000_ref12","first-page":"11","volume-title":"Handb Clin Neurol","author":"Basson","year":"2015"},{"issue":"2","key":"2024080207042719000_ref13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.sxmr.2015.11.009","article-title":"Hypoactive sexual desire disorder: a review of epidemiology, biopsychology, diagnosis, and treatment","volume":"4","author":"Parish","year":"2016","journal-title":"Sex Med Rev"},{"issue":"1","key":"2024080207042719000_ref14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3322\/caac.21319","article-title":"American Cancer Society\/American Society of Clinical Oncology breast cancer survivorship care guideline","volume":"66","author":"Runowicz","year":"2016","journal-title":"CA Cancer J Clin"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/21\/8\/709\/58710730\/qdae061.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/21\/8\/709\/58710730\/qdae061.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T07:16:20Z","timestamp":1722582980000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/21\/8\/709\/7690216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,10]]},"references-count":14,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,6,10]]},"published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jsxmed\/qdae061","relation":{},"ISSN":["1743-6095","1743-6109"],"issn-type":[{"value":"1743-6095","type":"print"},{"value":"1743-6109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,6,10]]}}}